Oragenics CEO To Present at The BIO CEO & Investor Conference on February 12th 2013

TAMPA, Fla.-- Oragenics, Inc. (OTCQB:OGEN) (OTCBB: OGEN), today announced Dr. John N. Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company and an update on activities at the BIO CEO & Investor Conference in New York City on Tuesday, February 12th at 1:15 pm EST. The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies.

“Oragenics is making progress with both our exclusive channel collaboration with Intrexon on novel lantibiotics and with our ProBiora3 containing oral probiotics for humans and pets.” stated Dr. Bonfiglio, President and CEO, Oragenics, Inc. “We remain focused on becoming a world leader in infectious disease and oral health.”

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130211005722/en/

Oragenics, Inc.
Michael Sullivan, 813-286-7900 x246
Chief Financial Officer
Direct: 813-786-6431
msullivan@oragenics.com

Source: Oragenics, Inc.

Released February 11, 2013